These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 29520813)

  • 1. A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer.
    Wu Y; Yu H; Zheng SL; Na R; Mamawala M; Landis T; Wiley K; Petkewicz J; Shah S; Shi Z; Novakovic K; McGuire M; Brendler CB; Ding Q; Helfand BT; Carter HB; Cooney KA; Isaacs WB; Xu J
    Prostate; 2018 Jun; 78(8):607-615. PubMed ID: 29520813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline mutations in PPFIBP2 are associated with lethal prostate cancer.
    Wu Y; Yu H; Zheng SL; Feng B; Kapron AL; Na R; Boyle JL; Shah S; Shi Z; Ewing CM; Wiley KE; Luo J; Walsh PC; Carter HB; Helfand BT; Cooney KA; Xu J; Isaacs WB
    Prostate; 2018 Dec; 78(16):1222-1228. PubMed ID: 30043417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
    Na R; Zheng SL; Han M; Yu H; Jiang D; Shah S; Ewing CM; Zhang L; Novakovic K; Petkewicz J; Gulukota K; Helseth DL; Quinn M; Humphries E; Wiley KE; Isaacs SD; Wu Y; Liu X; Zhang N; Wang CH; Khandekar J; Hulick PJ; Shevrin DH; Cooney KA; Shen Z; Partin AW; Carter HB; Carducci MA; Eisenberger MA; Denmeade SR; McGuire M; Walsh PC; Helfand BT; Brendler CB; Ding Q; Xu J; Isaacs WB
    Eur Urol; 2017 May; 71(5):740-747. PubMed ID: 27989354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prevalence of CHEK1 and CHEK2 Mutations in Prostate Cancer: a Retrospective Cohort Study.
    Alorjani M; Aburub M; Al-Trad B; Hamad MA; AbuAlarja M; Bashir SA; Al-Batayneh K; Zoubi MA
    Med Arch; 2023 Feb; 77(1):8-12. PubMed ID: 36919124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
    Näslund-Koch C; Nordestgaard BG; Bojesen SE
    J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
    Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium.
    Muranen TA; Blomqvist C; Dörk T; Jakubowska A; Heikkilä P; Fagerholm R; Greco D; Aittomäki K; Bojesen SE; Shah M; Dunning AM; Rhenius V; Hall P; Czene K; Brand JS; Darabi H; Chang-Claude J; Rudolph A; Nordestgaard BG; Couch FJ; Hart SN; Figueroa J; García-Closas M; Fasching PA; Beckmann MW; Li J; Liu J; Andrulis IL; Winqvist R; Pylkäs K; Mannermaa A; Kataja V; Lindblom A; Margolin S; Lubinski J; Dubrowinskaja N; Bolla MK; Dennis J; Michailidou K; Wang Q; Easton DF; Pharoah PD; Schmidt MK; Nevanlinna H
    Breast Cancer Res; 2016 Oct; 18(1):98. PubMed ID: 27716369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors.
    AlDubayan SH; Pyle LC; Gamulin M; Kulis T; Moore ND; Taylor-Weiner A; Hamid AA; Reardon B; Wubbenhorst B; Godse R; Vaughn DJ; Jacobs LA; Meien S; Grgic M; Kastelan Z; Markt SC; Damrauer SM; Rader DJ; Kember RL; Loud JT; Kanetsky PA; Greene MH; Sweeney CJ; Kubisch C; Nathanson KL; Van Allen EM; Stewart DR; Lessel D;
    JAMA Oncol; 2019 Apr; 5(4):514-522. PubMed ID: 30676620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis.
    Shi Z; Lu L; Resurreccion WK; Yang W; Wei J; Wang Q; Engelmann V; Zheng SL; Cooney KA; Isaacs WB; Helfand BT; Lu J; Xu J
    Prostate; 2022 Jan; 82(1):107-119. PubMed ID: 34674288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Clinical and Genetic Analysis of
    Kirchner K; Gamulin M; Kulis T; Sievers B; Kastelan Z; Lessel D
    Genes (Basel); 2022 Oct; 13(11):. PubMed ID: 36360192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHEK2 c.1100delC allele is rarely identified in Greek breast cancer cases.
    Apostolou P; Fostira F; Papamentzelopoulou M; Michelli M; Panopoulos C; Fountzilas G; Konstantopoulou I; Voutsinas GE; Yannoukakos D
    Cancer Genet; 2015 Apr; 208(4):129-34. PubMed ID: 25835597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.
    Bell DW; Kim SH; Godwin AK; Schiripo TA; Harris PL; Haserlat SM; Wahrer DC; Haiman CA; Daly MB; Niendorf KB; Smith MR; Sgroi DC; Garber JE; Olopade OI; Le Marchand L; Henderson BE; Altshuler D; Haber DA; Freedman ML
    Int J Cancer; 2007 Dec; 121(12):2661-7. PubMed ID: 17721994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients.
    Wendt C; Muranen TA; Mielikäinen L; Thutkawkorapin J; Blomqvist C; Jiao X; Ehrencrona H; Tham E; Arver B; Melin B; Kuchinskaya E; Stenmark Askmalm M; Paulsson-Karlsson Y; Einbeigi Z; von Wachenfeldt Väppling A; Kalso E; Tasmuth T; Kallioniemi A; Aittomäki K; Nevanlinna H; Borg Å; Lindblom A
    Sci Rep; 2021 Jul; 11(1):14763. PubMed ID: 34285278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients.
    Fan Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    Breast Cancer Res Treat; 2018 May; 169(1):59-67. PubMed ID: 29356917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel founder CHEK2 mutation is associated with increased prostate cancer risk.
    Cybulski C; Huzarski T; Górski B; Masojć B; Mierzejewski M; Debniak T; Gliniewicz B; Matyjasik J; Złowocka E; Kurzawski G; Sikorski A; Posmyk M; Szwiec M; Czajka R; Narod SA; Lubiński J
    Cancer Res; 2004 Apr; 64(8):2677-9. PubMed ID: 15087378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures.
    Ow GS; Ivshina AV; Fuentes G; Kuznetsov VA
    Cell Cycle; 2014; 13(14):2262-80. PubMed ID: 24879340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline genetic variants in men with prostate cancer and one or more additional cancers.
    Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
    Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of two induced pluripotent stem cell lines from blood cells of a prostate cancer patient carrying germline mutation in CHEK2.
    Liu R; Qian K; Xiao Y; Jiang W
    Stem Cell Res; 2021 May; 53():102299. PubMed ID: 33780728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline DNA Damage Response Gene Mutations in Localized Prostate Cancer.
    Januskevicius T; Vaicekauskaite I; Sabaliauskaite R; Matulevicius A; Vezelis A; Ulys A; Jarmalaite S; Jankevicius F
    Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38256334
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.